Mesothelioma Clinical Trial Targets Latest Gene Therapy

Pioneering pulmonologists Dr. Steven Albelda and Dr. Daniel Sterman have worked for more than 20 years on developing gene therapy to effectively combat pleural mesothelioma cancer. The payoff may have finally arrived. Albelda and Sterman’s long-awaited, phase III clinical trial will open this month to evaluate the efficacy of TR002, a novel gene therapy drug, when used in combination with celecoxib and gemcitabine. TR002, a form of immunotherapy, is a genetically engineered adenovirus that triggers the anti-tumor effects of interferon, a naturally occurring protein that destroys cancer cells. “The hope is, if it works like earlier studies have shown so far, that we may have a new treatment option, a new standard-of-care treatment to offer patients with mesothelioma,” said Sterman, director of pulmonary oncology at New York University Langone Medical Center. “We’re excited about the potential.” Earlier Study Was Impressive In an earlier, phase II study of TR002, the disease control rate was 87.5% for patients who either were newly diagnosed or were failed by standard chemotherapy. In second-line treatment, they had a median survival time of 17 months, almost double the historical control. The three-year survival rate was 20 percent. “A phase III trial gives us the possibility — we have no idea what the results will be — of having another important drug in our armamentarium with potentially proven benefits for mesothelioma p...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Authors: Xu W, Lou Y, Chen W, Kang Y Abstract Effective cancer therapy usually requires the assistance of well-designed drug carriers. In order to increase the drug accumulation to tumor tissue as well as to reduce the side effects of drug carriers, the hybrid drug delivery system (DDS) was developed by integrating folic acid (FA) and a metal-organic framework (MOF). The anticancer drug doxorubicin (DOX) was preloaded into the MOF nanoparticles during the synthesis process of the MOF nanoparticles. After surface modification with FA, the resulting FA/MOF/DOX nanoparticles were capable of serving as a biocompatible ...
Source: Biomedizinische Technik/Biomedical Engineering - Category: Biomedical Engineering Tags: Biomed Tech (Berl) Source Type: research
What are the latest strategies for fertility preservation in adolescent and young adult survivors of childhood cancer?Current Opinion in Urology
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Urology Journal Article Source Type: news
Publication date: Available online 12 October 2019Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): Alexandra Kollara, Premalatha Shathasivam, Soyeon Park, Maurice J. Ringuette, Theodore J. BrownAbstractStudies indicate androgens contribute to initiation or progression of epithelial ovarian cancer through poorly understood mechanisms. We provide evidence that the androgen receptor (AR) interacts in a ligand-independent manner with the putative armadillo repeat domain of ventricular zone expressed PH domain-containing 1 (VEPH1). This interaction was increased by mutation of the two nuclear receptor...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
This article reviews the major pathways by which adrenal steroids are converted to the potent male sex hormones, testosterone (T) and 5α-dihydrotestosterone (5α-DHT) and the discrete enzyme isoforms involved in castration resistant prostate cancer. Previous studies have mainly utilized radiotracers to investigate these pathways but have not used prevailing concentrations of precursors found in castrate male human serum. In addition, the full power of stable-isotope dilution liquid chromatography tandem mass spectrometry has not been applied routinely. Furthermore, it is clear that adaptive responses occur in th...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
Publication date: Available online 12 October 2019Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): Laura Tatiana Pelegrina, Myriam LaconiAbstractOvarian carcinoma is one of the most common cause of death by gynecologic cancer. Several epidemiological and in vitro studies have shown controversial data about progesterone effects in ovarian cancer. Progesterone can be converted in its active metabolite, allopregnanolone, its effects in ovarian cancer are still unknown. Previously, we demonstrated that allopregnanolone modifies ovarian morphophysiology, being able to alter critical process of tumor d...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
Publication date: Available online 12 October 2019Source: Sensors and Actuators B: ChemicalAuthor(s): Yucui Jiao, Chao Du, Lijun Zong, Xueying Guo, Yufeng Han, Xiaopan Zhang, Lin Li, Chengwu Zhang, Qiang Ju, Jinhua Liu, Hai-Dong Yu, Wei HuangAbstractA novel three-dimensional (3D) vertical-flow paper-based device (3VPD), integrated with a sandwich-type fluorescent immunoassay, was developed for multiplexed detection of cancer biomarkers simultaneously based on the principle of origami. The developed 3VPD, composed of a sample layer, a splitting layer, and a test layer, could be fabricated simply by wax-printing on paper at ...
Source: Sensors and Actuators B: Chemical - Category: Chemistry Source Type: research
This article demonstrates the fabrication of versatile nanoformulation by conveniently wrapping the ultrasmall platinum nanoparticles-dispersed over the zinc metal-doped mesoporous silica-based nanocarriers (Zn-MSNs) for not only conveying the drug cargo efficiently but also facilitating the advanced abilities of deep tumor penetration through interacting with adherens junctions and aphotic (dark) synergistic therapeutic effects to combat cancer multidrug resistance.
Source: Chemical Engineering Journal - Category: Chemistry Source Type: research
Publication date: Available online 13 October 2019Source: European UrologyAuthor(s): Bruce Montgomery, Stephen Plymate
Source: European Urology - Category: Urology & Nephrology Source Type: research
Drop in undergraduate applications attributed to the field's poor public image
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
ConclusionsHypoxia-regulated lncRNAs will undoubtedly be developed as targets and promote the progress in ideal therapies for gastrointestinal cancer patients.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
More News: Adenoviruses | Arthritis | Asbestosis | Australia Health | Cancer | Cancer & Oncology | Celebrex | Chemotherapy | Clinical Trials | Environmental Health | Finland Health | Gene Therapy | Genetics | History of Medicine | Hospitals | Immunotherapy | Mesothelioma | New York University | Rheumatology | Russia Health | Scotland Health | Study | UK Health | University of Maryland | University of Pennsylvania | USA Health